Vir Biotechnology president and CEO George Scangos explains why many companies struggle to build a sustainable business model around fighting infectious diseases, particularly when it comes to developing antibiotics. However, he adds, certain therapies for viral diseases are currently more financially viable. Dr. Scangos explores why Vir decided to go “all-in” on infectious diseases, how they built a company around that mission, and how the arrival of COVID-19 impacted the young company’s trajectory.
Related
Maëlle Gavet,
Techstars
Ruthless Empathy [Entire Talk]
Empathetic technology can empower companies to scale social good.
Maëlle Gavet,
Techstars
Ruthless Empathy [Entire Talk]
Empathetic technology can empower companies to scale social good.
Hemant Taneja,
General Catalyst
Build, Don’t Break [Entire Talk]
The bigger the impact, the greater the responsibility.
Hemant Taneja,
General Catalyst
Build, Don’t Break [Entire Talk]
The bigger the impact, the greater the responsibility.
Aicha Evans,
Zoox
Driving Innovation [Entire Talk]
Execute bold ideas with conviction.
Aicha Evans,
Zoox
Driving Innovation [Entire Talk]
Execute bold ideas with conviction.
